Abbott Labs Files 8-K on Financials

Ticker: ABT · Form: 8-K · Filed: 2025-10-15T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, sec-filing

Related Tickers: ABT

TL;DR

Abbott Labs filed an 8-K for financial updates, nothing major in this snippet.

AI Summary

On October 15, 2025, Abbott Laboratories filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or new operational details were disclosed in the provided excerpt.

Why It Matters

This filing indicates Abbott Laboratories is providing updates on its financial performance and condition to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine filing for financial reporting and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial results or conditions are being reported by Abbott Laboratories in this 8-K filing?

The provided excerpt states the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific results or conditions.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is October 15, 2025.

Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?

This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is Abbott Laboratories' state of incorporation and IRS Employer Identification Number?

Abbott Laboratories is incorporated in Illinois and its IRS Employer Identification Number is 36-0698440.

Where are Abbott Laboratories' principal executive offices located?

Abbott Laboratories' principal executive offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.

From the Filing

0001628280-25-045049.txt : 20251015 0001628280-25-045049.hdr.sgml : 20251015 20251015073348 ACCESSION NUMBER: 0001628280-25-045049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20251015 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251015 DATE AS OF CHANGE: 20251015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 251393399 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20251015.htm 8-K abt-20251015 0000001800 FALSE New York Stock Exchange CHX 0000001800 2025-10-15 2025-10-15 0000001800 exch:XCHI 2025-10-15 2025-10-15 0000001800 exch:XNYS 2025-10-15 2025-10-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _______________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 15, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) _______________________________________________________ Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification  No.) _______________________________________________________ 100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: ( 224 ) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange NYSE Texas Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition On October 15, 2025, Abbott Laboratories announced its results of operations for the third quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory c

View on Read The Filing